Stadexmin contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Stadexmin contains the azo colouring agents e.g., sunset yellow and ponceau 4R, which may cause allergic reactions.
Extreme caution should be exercised when use Stadexmin for:
- The elderly (> 60 years) and children.
- Pregnancy and breastfeeding women.
- Patients with congestive heart failure, recent myocardial infarction, or hypertension, in patients with diabetes mellitus, epilepsy, glaucoma, hypothyroidism, hepatic failure, osteoporosis, peptic ulceration, psychoses or severe affective disorders, and renal impairment.
- Patients with non-immune with chickenpox, herpes zoster and measles.
- Patients with angle-closure glaucoma, urinary retention, prostatic hyperplasia, or pyloroduodenal obstruction due to its anticholinergic adverse effects.
Stadexmin is not recommended in the presence of acute infections uncontrolled by appropriate antimicrobial therapy, patients with active or doubtfully quiescent tuberculosis. Live vaccines should not be given to patients receiving Stadexmin nor for at least 3 months afterwards; killed vaccines or toxoids may be given although the response may be attenuated.
During prolonged Stadexmin using, patients should be examined regularly. Sodium intake may need to be reduced and calcium and potassium supplements may be necessary.
Stadexmin can cause drowsiness, dizziness and psychomotor impairment in some patients. This is accentuated by taking alcoholic beverages or medicines containing alcohol or other sedatives. Stadexmin should be avoided when driving and controlling machine.
